Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/28/25
End: 09/30/27
Due: 09/30/28
Phase: N/A
Priority: Normal
Start: 10/05/17
End: 07/13/21
Due: 07/13/22
Phase: N/A
Priority: Normal
Start: 06/17/24
End: 07/01/25
Due: 07/01/26
Phase: N/A
Priority: Normal
Start: 02/19/21
End: 06/30/22
Due: 06/30/23
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue | NCT06656351 | 60 Degrees Pharmaceuticals LLC | user2@example.com | None | 2025-02-28 | 2027-09-30 | 2028-09-30 | - | - | 2025-07-14 |
| Long-Term Safety Study of Tafenoquine | NCT03320174 | 60 Degrees Pharmaceuticals LLC | user2@example.com | None | 2017-10-05 | 2021-07-13 | 2022-07-13 | - | - | 2025-07-14 |
| Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis | NCT06207370 | 60 Degrees Pharmaceuticals LLC | user2@example.com | None | 2024-06-17 | 2025-07-01 | 2026-07-01 | - | - | 2025-07-14 |
| Tafenoquine in Patients With Mild to Moderate COVID-19 | NCT04533347 | 60 Degrees Pharmaceuticals LLC | user2@example.com | None | 2021-02-19 | 2022-06-30 | 2023-06-30 | - | - | 2025-07-14 |
| Expanded Use in Persistent (B. Microti) Babesiosis | NCT06478641 | 60 Degrees Pharmaceuticals LLC | user2@example.com | None | - | - | - | - | - | 2025-07-14 |